Jessica Herek, NP
Nurse Practitioner · Saginaw, MINPI 1376176255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 695 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 695 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- EMD Serono, Inc.$1K
- UCB, Inc.$950
- Pfizer$702
- Biogen$639
- Amgen$633
- plus $6K from 37 others
What the payments were for
- Speaking & faculty fees$390%
- Food & beverage$13,00999%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,139 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 66 | $108,323 |
| BriviactBrivaracetam | 79 | $94,456 |
| Emgality PenGalcanezumab-Gnlm | 73 | $59,071 |
| NuplazidPimavanserin Tartrate | 12 | $57,726 |
| UbrelvyUbrogepant | 43 | $55,538 |
| Aimovig AutoinjectorErenumab-Aooe | 44 | $43,031 |
| AptiomEslicarbazepine Acetate | 28 | $34,897 |
| QuliptaAtogepant | 13 | $25,226 |
| RexultiBrexpiprazole | 13 | $24,926 |
| NourianzIstradefylline | 14 | $24,736 |
| Lacosamide | 155 | $22,061 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 19 | $15,847 |
| NayzilamMidazolam | 15 | $10,570 |
| Carbamazepine ErCarbamazepine | 39 | $10,209 |
| Levetiracetam | 310 | $9,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $702 | $108,32366 claims |
| UCB, Inc.Briviact, Nayzilam | $950 | $105,02694 claims |
| AbbVieUbrelvy, Qulipta | $2,719 | $80,76456 claims |
| Acadia Pharmaceuticals IncNuplazid | $219 | $57,72612 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $22 | $34,89728 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $509 | $24,92613 claims |
| Kyowa Kirin, Inc.Nourianz | $68 | $24,73614 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $174 | $2,70119 claims |
| Upsher-smith Laboratories LLCTopiramate | $18 | $1,51898 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Saginaw
- Davida KrugerDetroit$739K
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Lisa Astalos ChismWoodhaven$103K
- Martha GoetzPetoskey$101K
- Debra DegraffGrand Rapids$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.